Latest news
Vivani Medical Completes Dosing in Phase 1 Trial of Semaglutide Implant - The Clinical Trial VanguardThe Clinical Trial Vanguard · Fri, 07 Aug 2026 06:39:00 GMTVivani Medical Completes Enrollment, Dosing in Phase 1 SLIM-1 Trial - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 15:00:07 GMTVivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 12:21:46 GMTSemaglutide implant trial doses all 20 participants; data expected in November - Stock TitanStock Titan · Thu, 06 Aug 2026 12:00:00 GMTClearOne Cancels 437,500 First Finance Warrants at $5.00 Amid Cortigent Merger Process - TradingViewTradingView · Wed, 05 Aug 2026 21:03:15 GMTVivani Medical (VANI) to Announce Earnings on Wednesday - MarketBeatMarketBeat · Wed, 05 Aug 2026 14:12:08 GMTEnterprise value to EBITDA forward of Vivani Medical, Inc. – NASDAQ:VANI - TradingViewTradingView · Sat, 01 Aug 2026 07:15:01 GMTVivani Medical, Inc. Revenue Breakdown – NASDAQ:VANI - TradingViewTradingView · Sat, 01 Aug 2026 07:02:55 GMT